VABu Conditioning for Older Adults with Acute Myeloid Leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a chemotherapy regimen (VABu) combined with a stem-cell transplant for older adults (60+) with acute myeloid leukemia (a blood cancer) who previously responded well to Venetoclax-based treatment. The goal is to see if this approach improves outcomes after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years or older
- You have been diagnosed with acute myeloid leukemia (AML) with intermediate or high-risk disease
- Your AML previously responded to Venetoclax-based chemotherapy
- You have a matched donor available (a relative matched at least 5/10 or an unrelated donor matched at least 8/10 for bone-marrow proteins)
- Your heart, lungs, kidney, and liver function are adequate to tolerate the treatment
- You are healthy enough overall to undergo stem-cell transplant (limited medical problems, good physical activity level)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs, medium-dose cytarabine and venetoclax, as a follow-up treatment (consolidation) to keep leukemia from coming back. It is for older adults with intermediate or high-risk acute myeloid leukemia who have already achieved remission after their first round of therapy.
This trial tests whether giving Venetoclax and Azacitidine (VA) after your first remission helps keep you in remission before a stem cell transplant. It's for people with intermediate-risk AML who are planning to have a donor transplant.
This trial tests whether a reduced-intensity stem cell transplant or venetoclax-based pills work better for patients aged 60-75 with high-risk acute myeloid leukemia who are already in remission.
This trial tests whether adding venetoclax (a pill that targets cancer cells) to the standard chemotherapy regimen before a stem cell transplant improves outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It is for patients aged 12–60 whose cancer has specific high-risk features and who have a matched donor.
This trial tests a new combination of chemotherapy drugs before a stem cell transplant for people with acute myeloid leukemia (AML) in first remission who are not very fit or have other health problems. The goal is to make the transplant safer for these patients.
This trial tests the combination of venetoclax (a targeted pill) and azacitidine (a chemotherapy-like drug) as consolidation therapy after initial treatment in adults with high-risk acute myeloid leukemia (AML) who have achieved remission and are planning a stem cell transplant. The goal is to see if this combination helps prevent relapse before transplant.
Hear when a new Allogeneic Hematopoietic Stem Cell Transplantation Recipient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.